title: Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer.
abstract: BACKGROUND
  Primary androgen deprivation therapy (ADT) is a treatment option not only for advanced but also for localized prostate cancer. However, the appropriate duration for primary ADT for localized prostate cancer has not been defined and few studies have addressed this issue. In this study, we aimed to determine the appropriate duration of ADT for localized prostate cancer.
  
  
  METHODS
  Sixty-eight consecutive patients with localized prostate cancer who underwent a prostatectomy following neoadjuvant ADT were retrospectively reviewed. Factors associated with pT0, which is regarded as serious cancer cell damage or elimination, were investigated.
  
  
  RESULTS
  Of the 68 males, 24 (35.3%) were classified as pT0. The median duration of neoadjuvant ADT in the pT0 and non-pT0 groups was 9 months and 7.5 months, respectively (p = 0.022). The duration of neoadjuvant ADT from when PSA reached < 0.2 ng/ml to surgery was longer in the pT0 group than that in the non-pT0 group (median 5 months against 3 months, p = 0.011). pT0 was achieved in 5 of 6 patients (83.3%) who received ADT for ≥10 months after PSA reached < 0.2 ng/ml. No other clinical characteristics predicted conversion to pT0.
  
  
  CONCLUSIONS
  Continuous ADT for ≥10 months after PSA reached < 0.2 ng/ml induced serious prostate cancer cell damage in most patients (> 80%) and may be sufficient to treat localized prostate cancer.
authors.affiliation: Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan. n-fuji@med.uoeh-u.ac.jp
authors.forename: Naohiro
authors.initials: N
authors.lastname: Fujimoto
authors.forename: Tatsuhiko
authors.initials: T
authors.lastname: Kubo
authors.forename: Hideo
authors.initials: H
authors.lastname: Shinsaka
authors.forename: Masahiro
authors.initials: M
authors.lastname: Matsumoto
authors.forename: Shohei
authors.initials: S
authors.lastname: Shimajiri
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Matsumoto
mesh_terms: D000368:Aged; D000726:Androgen Antagonists / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D017024:Chemotherapy, Adjuvant; D006801:Humans; D008297:Male; D008875:Middle Aged; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists; D000970:Antineoplastic Agents